Go online to PeerView.com/YFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in neurology discuss advances in the early treatment of Alzheimer’s disease, including novel biomarkers and emerging disease-modifying therapies. Upon completion of this activity, participants should be better able to: Integrate novel biomarkers for the early detection and treatment of AD based on the latest evidence, Apply the latest clinical data on emerging treatments that target the underlying pathology of AD.

David Weidman, MD - Therapeutic Advances in the Early Treatment of Alzheimer’s Disease: Expert Insights on Novel Biomarkers and Emerging Disease-Modifying Therapies

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

Education

Training

Language Courses

Higher Education

K-12

Educational Technology

Medicine

Science & Medicine

Science

Health & Fitness

How To

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.  For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AMU865. CME credit will be available until April 2, 2025.  Navigating Advances in Alzheimer’s Disease: An Expert Consult on Integrating the New Diagnostic Tools and Disease-Modifying Therapies Into Your Clinical Practice   In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  SupportThis activity is supported by an educational grant from Eisai Inc.  Disclosure information is available at the beginning of the video presentation.

James E. Galvin, MD, MPH - Navigating Advances in Alzheimer’s Disease: An Expert Consult on Integrating the New Diagnostic Tools and Disease-Modifying Therapies Into Your Clinical Practice

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.  For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/MCV865. CME/AAPA credit will be available until March 14, 2025.  Improving the Recognition and Management of Amyloid-Related Imaging Abnormalities (ARIA) in Alzheimer’s Disease Treatment: Practical Tools & Strategies for Radiology & Neuroradiology Specialists    In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  SupportThis activity is supported by an educational grant from Lilly.  Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.  Faculty/Planner DisclosuresCo-Chair/PlannerJerome A. Barakos, MD, has no financial interests/relationships or affiliations in relation to this activity.  Co-Chair/PlannerTammie L.S. Benzinger, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Avid Radiopharmaceuticals/Lilly; Biogen; and Eisai Co., Ltd.Grant/Research Support from Hyperfine, Inc. and Siemens.  Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Jerome A. Barakos, MD / Tammie L.S. Benzinger, MD, PhD - Improving the Recognition and Management of Amyloid-Related Imaging Abnormalities (ARIA) in Alzheimer’s Disease Treatment: Practical Tools and 

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.  For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AWE865. CME credit will be available until December 27, 2024.  Brainstorming New Approaches to Improve Glioblastoma Care: Revolutionary Advances With Modern Gene Fusion–Targeted Therapy   In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  SupportThis activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.  Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.  Faculty/Planner DisclosuresChair/PlannerManmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.  Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Manmeet S. Ahluwalia, MD, MBA, FASCO - Brainstorming New Approaches to Improve Glioblastoma Care: Revolutionary Advances With Modern Gene Fusion–Targeted Therapy

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/NYF865. CME/NCPD/CPE/IPCE credit will be available until November 6, 2024.FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from argenx US, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJames F. Howard Jr., MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Argenx; Biologix Pharma; F. Hoffmann-La Roche Ltd.; Horizon Therapeutics plc; Immunovant, Inc.; Merck & Co., Inc./EMD Serono, Inc.; NMD Pharma A/S; Novartis Pharmaceuticals Corporation; Ra Pharmaceuticals, Inc./UCB Inc.; Regeneron Pharmaceuticals Inc.; Sanofi; Toleranzia AB; and Zai Lab.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Argenx; Cartesian Therapeutics, Inc.; and Ra Pharmaceuticals, Inc./UCB Inc.Speaker  for Alexion Pharmaceuticals, Inc.; Argenx; F. Hoffmann-La Roche Ltd; and Zai Lab.Faculty/PlannerAmy Clarke, MSN, RN, IgCN, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Grifols, S.A.; Kedrion Biopharma Inc.; Koru Pharma Co., LTD; Pfizer; and Takeda Pharmaceutical Company Limited.Faculty/PlannerClaire Spahn, PharmD, BCPS, has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

James F. Howard Jr., MD - FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/CRG865. CME/AAPA credit will be available until November 5, 2024.Building a Better Bridge: Providing Continuous SMA Care From Adolescence Through Adulthood In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerClaudia A. Chiriboga, MD, MPH, FAAN, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for F. Hoffmann-La Roche Ltd; Genentech, Inc.; and Novartis Pharmaceuticals Corporation/AveXis.Grant/Research Support from Biogen; Biohaven, Ltd.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; and Novartis Pharmaceuticals Corporation/AveXis.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

David Weidman, MD - Therapeutic Advances in the Early Treatment of Alzheimer’s Disease: Expert Insights on Novel Biomarkers and Emerging Disease-Modifying Therapies

Download our free app to listen on your phone